CoChat
Sign Up
Cited by 111

The DOI matches its Crossref record.

Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia

Johnson, Amy J., Lucas, David M., Muthusamy, Natarajan, Smith, Lisa L., Edwards, Ryan B., De Lay, Michael D., Croce, Carlo M., Grever, Michael R., Byrd, John C.·2006·Blood
DOI 10.1182/blood-2005-12-011213
Open this paper in CoChat — free account

Abstract

Drug development in human chronic lymphocytic leukemia (CLL) has been limited by lack of a suitable animal model to adequately assess pharmacologic properties relevant to clinical application. A recently described TCL-1 transgenic mouse develops a chronic B-cell CD5+ leukemia that might be useful for such studies. Following confirmation of the natural history of this leukemia in the transgenic mice, we demonstrated that the transformed murine lymphocytes express relevant therapeutic targets (Bcl-2, Mcl-1, AKT, PDK1, and DNMT1), wild-type p53 status, and in vitro sensitivity to therapeutic agents relevant to the treatment of human CLL. We then demonstrated the in vivo clinical activity of low-dose fludarabine in transgenic TCL-1 mice with active leukemia. These studies demonstrated both early reduction in blood-lymphocyte count and spleen size and prolongation of survival (P = .046) compared with control mice. Similar to human CLL, an emergence of resistance was noted with fludarabine treatment in vivo. Overall, these studies suggest that the TCL-1 transgenic leukemia mouse model has similar clinical and therapeutic response properties to human CLL and may therefore serve as a useful in vivo tool to screen new drugs for subsequent development in CLL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2005-12-011213

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 31

  1. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343: 1750-1757. · DOI
  2. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98: 2319-2325. · DOI
  3. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia: the French Cooperative Group on CLL. Lancet. 1996;347: 1432-1438. · DOI
  4. Roos J, Hennig I, Schwaller J, et al. Expression of TCL1 in hematologic disorders. Pathobiology. 2001;69: 59-66. · DOI
  5. Nakayama I, Murao S, Kitazawa S, Azumi A, Yamamoto M, Maeda S. Activation of the TCL1 protein in B cell lymphomas. Pathol Int. 2000;50: 191-199. · DOI
  6. Pekarsky Y, Koval A, Hallas C, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A. 2000;97: 3028-3033. · DOI · Paper page
  7. Laine J, Kunstle G, Obata T, Noguchi M. Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family. J Biol Chem. 2002;277: 3743-3751. · DOI
  8. Kunstle G, Laine J, Pierron G, et al. Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. Mol Cell Biol. 2002;22: 1513-1525. · DOI
  9. Virgilio L, Lazzeri C, Bichi R, et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci U S A. 1998;95: 3885-3889. · DOI
  10. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002;99: 6955-6960. · DOI · Paper page
  11. Johnson AJ, Smith LL, Zhu J, et al. A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood. 2005;105: 2504-2509. · DOI
  12. Zhu J, Huang JW, Tseng PH, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004;64: 4309-4318. · DOI
  13. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998;92: 3804-3816. · DOI
  14. Byrd JC, Shinn C, Ravi R, et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood. 1999; 94: 1401-1408. · DOI
  15. Kaplan EL MP. Nonparametric estimation from incomplete observations. J am Statist Assoc. 1958;43: 457-481. · DOI · Paper page
  16. Barcos M, Lane W, Gomez GA, et al. An autopsy study of 1206 acute and chronic leukemias (1958 to 1982). Cancer. 1987;60: 827-837. · DOI
  17. Thornton PD, Gruszka-Westwood AM, Hamoudi RA, et al. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J. 2004;5: 47-54. · DOI
  18. Di Raimondo F, Palumbo GA, Romeo MA, et al. Evaluation of Taxol cytotoxicity on B-CLL cells in vitro. Leuk Lymphoma. 1997;26: 115-119. · DOI
  19. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res. 1989;49: 4640-4647.
  20. Yan XJ, Albesiano E, Telusma G, Zanesi N, Croce CM, Chiorazzi N. The BCRs expressed by leukemia cells from TCL1 transgenic mice resemble those of unmutated B-CLL. Blood. 2005;106: 19a. Abstract 49. · DOI
  21. Gorgun G, Holderried AW, Ledieu R, Zahrieh D, Gribben JG. CLL cells in TCL1 transgenic mice induce similar defects in CD4 and CD8 T cells to those observed in patients with CLL. Blood. 2005; 106: 19a. Abstract 50. · DOI
  22. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119: 976-984. · DOI
  23. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood. 2000;96: 393-397. · DOI
  24. Mellors RC. Autoimmune disease in NZB-Bl mice, II: autoimmunity and malignant lymphoma. Blood. 1966;27: 435-448. · DOI
  25. Okada T, Takiura F, Tokushige K, et al. Major histocompatibility complex controls clonal proliferation of CD5+ B cells in H-2-congenic New Zealand mice: a model for B cell chronic lymphocytic leukemia and autoimmune disease. Eur J Immunol. 1991;21: 2743-2748. · DOI
  26. Su YC, Wu WM, Wu MF, Chiang BL. A model of chronic lymphocytic leukemia with Ritcher's transformation in severe combined immunodeficiency mice. Exp Hematol. 2001;29: 1218-1225. · DOI
  27. Kobayashi R, Picchio G, Kirven M, et al. Transfer of human chronic lymphocytic leukemia to mice with severe combined immune deficiency. Leuk Res. 1992;16: 1013-1023. · DOI
  28. Hummel JL, Lichty BD, Reis M, Dube I, Kamel-Reid S. Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies. Leukemia. 1996;10: 1370-1376.
  29. Shimoni A, Marcus H, Dekel B, et al. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human → mouse radiation chimera. Cancer Res. 1999;59: 5968-5974.
  30. Shimoni A, Marcus H, Canaan A, et al. A model for human B-chronic lymphocytic leukemia in human/mouse radiation chimera: evidence for tumor-mediated suppression of antibody production in low-stage disease. Blood. 1997;89: 2210-2218. · DOI
  31. National Center for Biotechnology Information. Entrez Nucleotide. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide. Accessed February 16, 2006.

Cited by

See all 111

Metadata

Authors
Johnson, A. J., Lucas, D. M., Muthusamy, N., Smith, L. L., Edwards, R. B., De Lay, M. D., Croce, C. M., Grever, M. R., & Byrd, J. C.
Affiliations
From the Division of Hematology and Oncology, Departments of Internal Medicine and Molecular Virology, Immunology, and Medical Genetics, College of Medicine, and Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus.
Venue
Blood
Publisher
American Society of Hematology
Published
2006-08-15
Volume
108
Issue
4
Pages
1334-1338
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2005-12-011213
Cited by
111
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. https://app.cochat.ai/papers/10.1182/blood-2005-12-011213
The paper
Johnson, A. J., Lucas, D. M., Muthusamy, N., Smith, L. L., Edwards, R. B., De Lay, M. D., Croce, C. M., Grever, M. R., & Byrd, J. C. (2006). Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood. https://doi.org/10.1182/blood-2005-12-011213